Company / SG&A Expense
CHAMPIONS ONCOLOGY, INC. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$11.1M
FY2025
5-year range
$6.5M / $11.1M
FY2021-FY2025
Trend
+18.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has increased for 3 consecutive years, from $7M in FY2022 to $11M in FY2025.
Based on SEC 10-K filings.
$11M in FY2025 with a 5-year CAGR of +11.2%.
Increased from $9M to $11M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +19.3%
- 5-Year CAGR
- +11.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- CHAMPIONS ONCOLOGY, INC.'s sg&a expense has grown for 3 consecutive years.
- 5-year CAGR of +11.2%, indicating consistent growth.
- In FY2025, sg&a expense increased 18.5% year-over-year.
- Lowest sg&a expense in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.23 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $11.1M | +18.5% |
| FY2024 | $9.3M | +2.4% |
| FY2023 | $9.1M | +40.0% |
| FY2022 | $6.5M | -1.5% |
| FY2021 | $6.6M | +1.6% |
| FY2020 | $6.5M | -1.5% |
| FY2019 | $6.6M | +33.3% |
| FY2018 | $5.0M | -4.1% |
| FY2017 | $5.2M | -3.1% |
| FY2016 | $5.3M | -12.8% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026